NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 129 filers reported holding NURIX THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,391,780 | -21.6% | 2,848,827 | -0.3% | 1.06% | -2.8% |
| Q2 2023 | $28,544,517 | +16.9% | 2,857,309 | +3.9% | 1.10% | +3.5% |
| Q1 2023 | $24,414,530 | -25.9% | 2,749,384 | -8.4% | 1.06% | -21.4% |
| Q4 2022 | $32,948,608 | -15.9% | 3,000,784 | -0.2% | 1.35% | -11.3% |
| Q3 2022 | $39,177,000 | +2.8% | 3,006,684 | 0.0% | 1.52% | +4.5% |
| Q2 2022 | $38,095,000 | -9.9% | 3,006,684 | -0.4% | 1.46% | +10.2% |
| Q1 2022 | $42,293,000 | -50.6% | 3,018,784 | +2.0% | 1.32% | -32.2% |
| Q4 2021 | $85,642,000 | -7.6% | 2,958,284 | -4.4% | 1.95% | +20.5% |
| Q3 2021 | $92,669,000 | +9.5% | 3,093,077 | -3.0% | 1.62% | +29.1% |
| Q2 2021 | $84,633,000 | -17.9% | 3,190,077 | -3.7% | 1.25% | -13.7% |
| Q1 2021 | $103,036,000 | +10.1% | 3,314,117 | +16.4% | 1.45% | +28.1% |
| Q4 2020 | $93,581,000 | +3.4% | 2,846,125 | +9.7% | 1.13% | -31.8% |
| Q3 2020 | $90,542,000 | – | 2,593,570 | – | 1.66% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |